189
Participants
Start Date
June 9, 2014
Primary Completion Date
March 27, 2017
Study Completion Date
April 12, 2017
Presatovir
Presatovir 200 mg (4 x 50 mg tablets) administered orally
Presatovir placebo
Presatovir placebo tablets administered orally
Northwestern Memorial Hospital, Chicago
Anne Arundel Medical Center, Annapolis
Henry Ford Health System, Detroit
William Beaumont, Royal Oak
New York Presbyterian Hospital, New York
Rochester General Hospital, Rochester
Vanderbilt Medical Group and Clinic, Nashville
University of Washington, Seattle
Marshfield Clinic Research Foundation, Marshfield
John Hunter Hospital, New Lambton
Westmead Hospital, Westmead
Redcliffe Hospital, Redcliffe
Gold Coast Hospital, Southport
Monash Medical Center, Clayton
Frankston Hospital, Frankston
Universite Liebre de Bruxelles - Hopital Erasme, Anderlecht
Hopital Foch, Suresnes
CHRU Brest - Hospital Cavale Blanche, Brest
Hopital d'Instructions des Armees Percy, Clamart
Hopital Louis Mourier, Colombes
Hopital Saint Louis - Service de Pneumologie, Paris
Hopital Tenon, Paris
Soroka Medical Center, Beersheba
Edith Wolfson Medical Center, Holon
Hadassah University Hospital Ein Kerem, Jerusalem
Meir Medical Center, Kefar Sava
Western Galilee Hospital-Nahariya, Nahariya
The Nazareth Hospital, Nazareth
Rabin Medical Center, Petah Tikva
Chaim Sheba Medical Center, Ramat Gan
Sourasky Medical Center, Tel Aviv
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
Gelre Ziekenhuizen, Zutphen
Tauranga Hospital, Tauranga
Middlemore Hospital, Auckland
Waikato Hospital, Hamilton
Centrum Badan Klinicznych, Wroclaw
Soon Chun Hyang University Hospital, Bucheon-si
Gachon University Gil Hospital, Incheon
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Southampton University Hospitals NHS Trust, Southampton
Princess Royal Hospital, Telford
Lead Sponsor
Gilead Sciences
INDUSTRY